Meso Developing Active

바이오텍 부활: M&A 활동 및 시장 성과

점수
0.4
모멘텀
▲ 0.0
기사
13
출처
2

요약

다음과 같은 내용을 다루는 기사는 이 내러티브에 속합니다: 바이오테크 시장의 회복, M&A 활동, 그리고 전체 시장 실적에 초점을 맞춘 논의.

관련 기사

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

Yahoo Finance · 3월 21, 2026
Mixed

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year

Nasdaq · 3월 20, 2026
Mixed

My Top 3 Drug Stocks for March 2026

Nasdaq · 3월 20, 2026
Bearish

Why biotech is back: IBT portfolio manager’s view

Yahoo Finance · 3월 20, 2026
Mixed

출처

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s … Yahoo Finance
2 Healthcare Stocks That Could Soar Over the Next 5 … Nasdaq
Moderna Stock is Soaring. Is It Too Late to Buy? Nasdaq
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance … Yahoo Finance
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but … Nasdaq
This Biotech Was Quietly Bought Before a $58 Per Share … Yahoo Finance
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, … Yahoo Finance
This $91 Million Position Signals Conviction in a Biotech Stock … Nasdaq
My Top 3 Drug Stocks for March 2026 Nasdaq
2 Healthcare Stocks to Buy Before They Get Bought Out Nasdaq
Why biotech is back: IBT portfolio manager’s view Yahoo Finance

타임라인

최종 업데이트 3월 20, 2026